MiR-144: A New Possible Therapeutic Target in Cancers

Kooshkaki, Omid; Rezaei, Zohre; Rahmati, Meysam; Vahedi, Parviz; Derakhshani, Afshin; Brunetti, Oronzo; Baghbanzadeh, Amir; Mansoori, Behzad; Silvestris, Nicola; Baradaran, Behzad

doi:10.20944/preprints202003.0034.v1

Cited by 4 publications

(1 citation statement)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both hsa-miR-21-5p and hsa-miR-221-3p are onco-miRNAs, and hsa-miR-21-5p was found upregulated in melanoma tissues, and in vitro experiments have established its role in cell cycle regulation by targeting the cyclin-dependent kinase inhibitor 2C (CDKN2C) (9). On the contrary, hsa-miR-200c-3p and hsa-miR-144-3p are onco-suppressor microRNAs (10,11), however, hsa-miR-200c-3p is highly expressed in serum and plasma of patients with others solid tumors (12-14). Other dysregulated microRNAs are hsa-miR-134-5p and hsa-miR-150-5p, and hsa-miR-134-5p is involved in the regulation of cell proliferation, apoptosis, invasion, and drug resistance; only recently, its expression was investigated in liquid biopsies from patients with melanoma (7,15).…”

Section: Introductionmentioning

confidence: 99%

A group of three miRNAs can act as candidate circulating biomarkers in liquid biopsies from melanoma patients

et al. 2023

View full text Add to dashboard Cite

BackgroundStaging of melanoma and follow up after melanoma diagnosis aims at predicting risk and detecting progression or recurrence at early stage, respectively in order to timely start and/or change treatment. Tumor thickness according to Breslow, status of the sentinel node and value of the lactate dehydrogenase (LDH) are well-established prognostic markers for metastatic risk, but reliable biomarkers identifying early recurrence or candidates who may benefit best from medical treatment are still warranted. Liquid biopsy has emerged to be a suitable method for identifying biomarkers for early cancer diagnosis, prognosis, therapeutic response prediction, and patient follow-up. Liquid biopsy is a blood-based non-invasive procedure that allows analyzing circulating analytes, including extracellular vesicles.MethodsIn this study we have explored the use of 7 miRNAs, namely hsa-miR-149-3p, hsa-miR-150-5p, hsa-miR-21-5p, hsa-miR-200c-3p, hsa-miR-134-5p, hsa-miR-144-3p and hsa-miR-221-3p in plasma exosomes to discriminate melanoma patients from controls without melanoma in a cohort of 92 individuals.Results and discussionOur results showed that three out seven miRNAs, namely hsa-miR-200c-3p, hsa-miR-144-3p and hsa-miR-221-3p were differentially expressed in plasma-derived exosomes from melanoma patients and controls. Furthermore, the expression of the three miRNAs may be a promising ancillary tool as a melanoma biomarker, even for discriminating between nevi and melanoma.

show abstract

Section: Introductionmentioning

confidence: 99%

A group of three miRNAs can act as candidate circulating biomarkers in liquid biopsies from melanoma patients

et al. 2023

View full text Add to dashboard Cite

show abstract

MicroRNA, mRNA, and Proteomics Biomarkers and Therapeutic Targets for Improving Lung Cancer Treatment Outcomes

Raese

Luo

et al. 2023

Cancers

View full text Add to dashboard Cite

The majority of lung cancer patients are diagnosed with metastatic disease. This study identified a set of 73 microRNAs (miRNAs) that classified lung cancer tumors from normal lung tissues with an overall accuracy of 96.3% in the training patient cohort (n = 109) and 91.7% in unsupervised classification and 92.3% in supervised classification in the validation set (n = 375). Based on association with patient survival (n = 1016), 10 miRNAs were identified as potential tumor suppressors (hsa-miR-144, hsa-miR-195, hsa-miR-223, hsa-miR-30a, hsa-miR-30b, hsa-miR-30d, hsa-miR-335, hsa-miR-363, hsa-miR-451, and hsa-miR-99a), and 4 were identified as potential oncogenes (hsa-miR-21, hsa-miR-31, hsa-miR-411, and hsa-miR-494) in lung cancer. Experimentally confirmed target genes were identified for the 73 diagnostic miRNAs, from which proliferation genes were selected from CRISPR-Cas9/RNA interference (RNAi) screening assays. Pansensitive and panresistant genes to 21 NCCN-recommended drugs with concordant mRNA and protein expression were identified. DGKE and WDR47 were found with significant associations with responses to both systemic therapies and radiotherapy in lung cancer. Based on our identified miRNA-regulated molecular machinery, an inhibitor of PDK1/Akt BX-912, an anthracycline antibiotic daunorubicin, and a multi-targeted protein kinase inhibitor midostaurin were discovered as potential repositioning drugs for treating lung cancer. These findings have implications for improving lung cancer diagnosis, optimizing treatment selection, and discovering new drug options for better patient outcomes.

show abstract

Correlation between Circulating miR-16, miR-29a, miR-144 and miR-150, and the Radiotherapy Response and Survival of Non-Small-Cell Lung Cancer Patients

Bache,

Kadler,

Struck

et al. 2023

IJMS

View full text Add to dashboard Cite

Despite the success of current therapy concepts, patients with advanced non-small-cell lung cancer (NSCLC) still have a very poor prognosis. Therefore, biological markers are urgently needed, which allow the assessment of prognosis, or prediction of the success of therapy or resistance in this disease. Circulating microRNAs (miRs) have potential as biomarkers for the prognosis and prediction of response to therapy in cancer patients. Based on recent evidence that circulating miR-16, miR-29a, miR-144 and miR-150 can be regulated by ionizing radiation, the concentration of these four miRs was assessed in the plasma of NSCLC patients at different time points of radiotherapy by digital droplet PCR (ddPCR). Furthermore, their impact on patients’ prognosis was evaluated. The mean plasma levels of miR-16, miR-29a, miR-144 and miR-150 significantly differed intra- and inter-individually, and during therapy in NSCLC patients, but showed a strong positive correlation. The individual plasma levels of miR-16, miR-29a and miR-144 had prognostic value in NSCLC patients during or at the end of radiotherapy in Cox’s regression models. NSCLC patients with low levels of these three miRs at the end of radiotherapy had the worst prognosis. However, miR-150 plasma levels and treatment-dependent changes were not predictive. In conclusion, circulating miR-16, miR-29a and miR-144, but not miR-150, have a prognostic value in NSCLC patients undergoing radiotherapy.

show abstract

MiR-144: A New Possible Therapeutic Target in Cancers

Cited by 4 publications

References 73 publications

A group of three miRNAs can act as candidate circulating biomarkers in liquid biopsies from melanoma patients

A group of three miRNAs can act as candidate circulating biomarkers in liquid biopsies from melanoma patients

MicroRNA, mRNA, and Proteomics Biomarkers and Therapeutic Targets for Improving Lung Cancer Treatment Outcomes

Correlation between Circulating miR-16, miR-29a, miR-144 and miR-150, and the Radiotherapy Response and Survival of Non-Small-Cell Lung Cancer Patients

Contact Info

Product

Resources

About